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1. Introduction
Gastric cancer is one of the most commonly occurring malignant cancers in the world. Dur‐
ing the second half of the 20th century a drastic rise has been observed in the number of cases
and deaths caused by this cancer. Gastric cancer is the second, after pulmonary cancer,
cause of death due to malignant cancers in the world. There is a geographic diversification
in the occurrence of gastric cancer. Most cases are recorded in Japan, China, South America,
and significantly less in Western Europe and in the United States [1].
The frequency of the occurrence of gastric cancer throughout the world is conditioned by
various factors. The following factors increase the risk of occurrence of gastric cancer: chron‐
ic atrophic gastritis with intestinal metaplasia, peptic ulcer, dysplasia, partial gastrectomy
and polyps. Environmental factors which can cause an increase in the risk of occurrence of
gastric cancer include, among others, dietary factors, smoking as well as a Helicobacter pylori
infection [2].
2. Risk factors in gastric cancer
2.1. Age
One of the risk factors for contracting gastric cancer is age (above 45 years of age). The num‐
ber of cases involving this tumor increases with age, reaching a peak between the ages of 50
and 70 [3,4]. Most deaths are recorded in the 55-75 age group; and the number of fatalities
decreases after 75. The frequency of gastric cancer occurrence rising with age can be ex‐
plained by the accumulation of somatic mutations connected with the occurrence of malig‐
nant tumors [5,1].
© 2013 Czyzewska; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2.2. Sex
Gastric cancer definitely develops more often in men. The coefficient of contracting this type
of cancer is 1.8 – 2 times higher for men in comparison to women. Generally, percentages
show 68% of gastric cases to be men and only 32% to be women [3, 6].
2.3. Obesity
Obesity is one of the causes facilitating spreading of the cancer in the cardia since discharg‐
ing of food contents into the esophagus can occur. Research results have indicated a 2.3- fold
increase of the risk of contracting gastric cancer in the cardia in obese persons in comparison
to non-obese people [4]. It has been shown that obesity in men (BMI ≥ 30 kg/m2) was con‐
nected not only to an increased risk of development of gastric cancer but also of colorectal
cancer, cancers of the liver and the gallbladder. In turn, obesity in women (BMI ≥ 30 kg/m2)
was tied to an increased risk of development of tumors of the liver, pancreas and breasts in
women above 50 years of age [7].
2.4. Diet
Diet, especially one rich in salt, smoked or marinated foods, grilled meat or smoked fish,
preserved food, rich in red meat, deficient in vitamins and antioxidants, significantly in‐
creases the probability of cancer occurrence. Salt and consumption of salted foods causes an
increase in the risk of stomach cancer occurrence even up to 50-100%. This happens because
sodium chloride damages the mucous membrane of the stomach leading to infections and
consequently facilitates colonization and growth of Helicobacter pylori. Increasing the supply
of salt while at the same time decreasing the number of consumed fruit and vegetables is
particularly dangerous [2, 3, 8].
This risk can be reduced by increasing the amount of vegetables and fruit consumed. In‐
creasing the number of consumed vegetables and fruit in every day diet reduces the risk of
contracting gastric cancer by as much as 30-50%. It is connected to the antioxidant effect of
the substances contained in vegetables such as ascorbic acid (vitamin C), carotenoids and ta‐
copherols. Moreover, soy products and green tea reduce the risk of contracting this type of
cancer. Catechins contained in green tea inhibit polyphenol nitrosation, have an anti-inflam‐
matory and antineoplastic effect modulating the path of signal transfer, inhibiting cell prolif‐
eration and transformation, as well as inducement of apoptosis, and in effect inhibit the
development of tumors [4,8].
Reducing the amount of chemically preserved products in the foods ingested also contrib‐
utes to reducing the risk of gastric cancer occurrence. Antioxidants such as vitamins C and
E, beta-carotene, or microelements like selenium, zinc or magnesium [2] have a protective
effect.
2.5. Stimulants
The risk of gastric cancer development correlates with the frequency and duration of smok‐
ing cigarettes. A nearly 5-fold increase occurs in the probability of contracting this disease in
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persons who smoke over 20 cigarettes a day and using alcohol more than 5 times in a two
week period of time. Furthermore, the probability of contracting this type of cancer in‐
creased approximately 1.3 times for passive smokers in comparison to people who do not
smoke and are not passive smokers. This is caused by the carcinogenic effects contained in
cigarette smoke (for example tar and its polycyclic hydrocarbons) [3-5,9]. Carcinogens are
able to form covalent bonds with DNA, which alters the correct function of the DNA and
can lead to the development of gastric cancer [10].
Similarly, overuse of spirits, especially those with high alcohol content, significantly increas‐
es the risk of contracting gastric cancer and other tumors of the digestive tract (cancers of
the mouth, throat, larynx and esophagus). Overconsumption of alcohol (4 or more drinks a
day) is connected to a significant increase in the risk of contracting gastric cancer, equally for
smokers as well as non-smokers (10). Alcohol stimulates the production of gastric juices and
gastric motility. Intragastric supply of 70-100% ethanol causes extensive mucous membrane
damage, with simultaneous reduction of blood flow in the blood vessels of the stomach, re‐
duced generation of mucus, increase in the activity of proinflammatory cytokines (including
IL-1), tumor necrosis factor alpha (TNFα), the level of leucotriene B4 and causing of oxida‐
tive stress [11].
Ethanol is not a carcinogen but the nitrosamines present in alcoholic beverages, especially in
vodka, can be responsible for heightened risk of gastric cancer development. Acetic alde‐
hyde, a metabolite of ethanol, is a known to be a carcinogen in animals. Acetic aldehyde cre‐
ated during ethanol metabolizing is mainly eliminated from the organism by aldehyde
dehydrogenase-2 (ALDH2). ALDH2 is polymorphic and in people it has two alleles:
ALDH2*1 and ALDH2*2. Reduced activity of the enzyme ALDH2*2 in homozygous indi‐
viduals results in approximately 6-20 times higher level of acetic aldehyde in blood in com‐
parison to homozygote ALDH2*1 and is connected with an elevated risk of developing
gastric cancer [10].
2.6. Medicines
Aspirin is one of the medicines which increase the risk of contracting gastric cancer. For peo‐
ple who regularly take aspirin the risk of contracting gastric cancer increases up to 30%.
Regular application of non-steroid anti-inflammatory drugs (NSAID) increased the risk of
developing peptic ulcers and digestive tract bleeding, while at the same time, depending on
the dosage, decreasing the growth of H. pylori and bacterial virulence factors. Aspirin in‐
creases the permeability of the external bacterial membrane causing an increased sensitivity
of H. pylori to antibiotics [12]. Occurrence of damage to the gastric mucosa (bleeding and ul‐
ceration of the stomach, duodenum and small intestine) connected to aspirin intake at a dos‐
age of 75-325 mg/day has been described. In patients taking aspirin occasionally bleeding of
the digestive tract occurred 5.5 times more often and in patients regularly taking this drug
approximately 7.7 times more frequently in relation to persons who did not take aspirin [13].
Furthermore, aspirin significantly decreases the amount of claudin-7, a protein produced by
the MNK28 cells, connected to damage of the digestive tract and aspirin related dysfunction
of the epithelium in the stomach. Aspirin related concentration decrease of the protein clau‐
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din-7 has been completely eradicated by the SB-203580 (inhibitor p38MAPK) treatment.
These results demonstrate that the protein claudin-7 plays a significant role in the occur‐
rence of aspirin related dysfunction of the stomach and that the activation of p28MAPK also
takes a part in this dysfunction [14].
On the other hand it has been shown that patients who regularly take NSAIDs had a signifi‐
cantly reduced risk of gastric cancer occurrence in relation to persons occasionally taking
these drugs or not taking them at all. However, the protective role of the NSAIDs was ob‐
served only in patients with non-cardia gastric cancer [15].
2.7. H. pylori infection
In many studies a close connection has been shown between a Helicobacter pylori (H. pylori)
infection and an infection of the mucous membrane of the stomach wall, peptic ulcer and
cancer [4]. The World Health Organization (WHO) classified H. pylori as a group 1 carcino‐
gen, even though the exact mechanism through which this bacterium contributes to the de‐
velopment of gastric cancer is not completely understood [5]. It has been ascertained that in
patients with an H. pylori infection the risk of the development of gastric cancer increases
seven fold in comparison with a group of people without such an infection. It seems that an
H. pylori infection connected with cagA genes (cytotoxin-associated gene A) and VacA (valu‐
locating cytotoxin A) induces a more severe infection [6]. These genes are responsible for the
production of cytotoxins which increase virulence. Especially the presence of Helicobacter py‐
lori CagA + contributes to the rise of the risk of carcinogenesis occurrence. CagA intensifies
immunological response, and through stimulation releases IL-8, a chemokine which leads to
damage to the mucosa [4,16,17]. Additionally, Helicobacter pylori produce large amounts of
urease which breaks urea into ammonia and carbon dioxide. The ammonia neutralizes the
hydrochloric acid contained in stomach juices leading to it gaining a higher pH therefore
making it easier for the bacteria to survive and reproduction [18]. Chronic inflammation
caused by a Helicobacter pylori infection can result in damage to cell DNA by disrupting anti‐
oxidant processes, while at the same time raising the level of reactive forms of oxygen, as
well as the amount of nitric oxide (NO), eventually elevating the risk of carcinogenesis.
What is more, Helicobacter pylori causes the release of interleukins such as IL-1β, IL-6, IL-8,
IL-18 as well as of the tumor necrosis factor α (TNF-α), through this intensifying the immu‐
nological response of the body and development of cancer[19, 16, 20].
H. pylori have a carcinogenic effect in the stomach through one of two possible mechanisms:
i. direct transformation of the stomach’s mucous membrane using the metabolic
products of the body or
ii. quick transformation of the mucosa cells causing infection related damage to the
mucous membrane which may elevate the risk of DNA damage, predisposing the
mucosa to transformation by absorption or endogenic mutagens [21] and byprod‐
ucts of the infection [22] such as peroxides and hydroxyl ions which can cause oxi‐
dative damage, mutation and malignant transformation [23].
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Furthermore, it has been proven that the eradication of H. pylori in patients below the age of
40 can reduce the risk of gastric cancer occurrence [24].
2.8. Epstein-Barr virus infection
The Epstein-Barr virus (EBV) is a herpes gamma virus, which causes opportunistic lympho‐
mas in immunologically compromised hosts, and in individuals without immunologic sup‐
pression. Mechanisms of EBV- related tumorigenesis may include:
• DNA methylation, which regulates host gene expressions and signal pathway through vi‐
ral proteins
• viral small RNAs that can target host genes
• altered expression of microRNAs (miRNA) of host cells and
• other epigenetic alterations (chromatin conformation and histone modification) [25].
It has been shown that the frequency of EBV infections in patients with gastric cancer differs
in different countries and ranges from 1.3% to 20.1%, an average of approximately 10%. In
association with the presence of the EBV in cancerous cells this type of gastric cancer has
been called the EBV-associated gastric carcinoma (EBVaGC). EBVaGC is a non-endemic dis‐
ease since it is distributed throughout the world. This carcinoma shows some distinct clini‐
copathologic characteristics, such as male predominance, predisposition to the proximal
part of the stomach, and a high proportion in diffuse-type gastric carcinomas. Also, EB‐
VaGC shows some characteristic of molecular abnormality, like global and nonrandom
CpG-island methylation of the promoter region of many cancer-related genes (p16, p73,
CDH1). EBVaGC presents a relatively favorable prognosis [26-30].
2.9. Socioeconomic status
Throughout the world in 2002 2/3 of gastric cancer cases have been recorded in less devel‐
oped nations. The poorest countries, especially African nations, stand out as having a rela‐
tively low morbidity coefficient for this type of tumor. However, this is caused by
insufficient diagnosis and status of medical care [19]. Performance of some professions such
as: butcher, farmer or fisherman predisposes one to an elevated risk of developing stomach
cancer. This is associated with being exposed to herbicides or nitrates during work. Other
professions exposed to a greater danger of carcinogenesis are: mechanic, manager, produc‐
tion supervisor as well as craftsmen, people working in stone quarries, metal industry, food
industry, cooks, people working in laundries and cleaning personnel [19,31].
2.10. Migration
A reduction in the incidence of cancer is observed in an event of migration from an environ‐
ment with a high risk coefficient to those having a lower coefficient, for example, migration of
citizens of Japan to the United States. A significant fall in the occurrence of gastric cancer is ob‐
served in persons of Japanese origin born in the United States in comparison to recent immi‐
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grants [9]. Studies done on immigrants to the United States from countries with a high risk of
gastric cancer occurrence, such as Japan or Poland, showed that subsequent generations of
émigrés to the USA slowly become similar through following generations to native citizens of
the country of settlement, meaning the risk of contracting the disease decreases [6].
2.11. Peptic ulcer
Patients suffering from gastric cancer often report having long lasting peptic ulcer disease of
the stomach or the duodenum or gastrointestinal reflux disease. The symptoms of the dis‐
eases mentioned above and symptoms of early stages of gastric cancer are practically indis‐
tinguishable if correct forms of diagnostics are not utilized [32].
2.12. Family history of gastric cancer
Family history of gastric cancer has been studied in many regions including Eastern Asia,
North America, Northern Europe and the nations of the Mediterranean region. Most cases
of family history of gastric cancer have been recorded in the countries of the Mediterranean
while the fewest cases of this type of disease have occurred in the countries of Western Eu‐
rope. Additionally, it has been shown that family history of gastric cancer more often con‐
cerns women than men [33].
Occurrence of gastric cancer within a family significantly increases the risk of carcinogene‐
sis. This is connected with similar environmental conditions in which a given family lives,
genetic predispositions, habits, like smoking tobacco or a Helicobacter pylori infection [34,35].
Development of gastric cancer is observed in approximately 10 – 15% of people with the dis‐
ease previously occurring among family members. Furthermore, the danger connected with
the occurrence of gastric cancer in immediate family increases about 2 – 3 fold in families
who are hereditarily degenerate [9,3]. Approximately 30% of gastric cancer cases connected
to earlier occurrence of this tumor in family is linked to a mutation in the e-cadherine coding
CDH1 gene [36].
Mutations in the e-cadherine coding gene (CDH1) lead to the inhibition of the reuptake of e-
cadherine by the product of the APC gene as a result of which an intensification of the in‐
flammatory response is observed. This results in an emergence of linitis plastica, a cancer
which develops without the presence of Helicobacter pylori infection or chronic gastritis [4].
2.13. Level of pepsinogen in serum
Pepsinogen is a proenzyme of pepsin, a digestive enzyme produced in the mucous mem‐
brane of the stomach. Two subtypes of pepsinogen can be distinguished (sPG): pepsinogen I
and pepsinogen II. Both subtypes are produced by chief cells, mucous neck cells and fundic
glands. Pepsinogen II is also produced by the pyloric gland cells. When atrophy develops in
the stomach, chief cells and fundic glands are replaced by pyloric gland cells, which leads to a
decrease of the pepsinogen I level while the level of pepsinogen II remains unchanged. For
this reason low levels of pepsinogen I and II are a good indicator of atrophic gastritis. Chronic
atrophic gastritis is a precursor of gastric cancer, especially intestinal-type cancers. Hence des‐
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ignation of the level of pepsinogen in serum or the calculation of the coefficient of pepsinogen
I/II is a good screening assay for gastric cancer. The ≤ 59 ng/ml level of pepsinogen I in serum
and the ≤3.9 value of the coefficient of pepsinogen I/II have been regarded as the most predic‐
tive. The sensitivity of this test was 71% while the specificity reached 69.2% [37].
2.14. Single Nucleotide Polymorphisms (SNAPs)
2.14.1. Polymorphism of IL1B
Interleukin 1 beta (IL1B) is a proinflammatory cytokine which regulates the expression of
some particles taking part in the inflammation process. It has been shown that the two func‐
tionally important polymorphisms in the promoter region, IL1B-31T/C and -511C/T, are con‐
nected to an increased risk of developing gastric cancer [38, 39].
2.14.2. Polymorphism of IL-8
IL-8 is a member of the α-chemokine family which acts as a strong chemoattractant and neu‐
rofilia activator. It has been suggested that this interleukin is strongly associated with the
processes of carcinogenesis, angiogenesis, adhesion, invasion and metastasis. Hull et al.
demonstrated the presence of a polymorphism of a single nucleotide in the -251 (A/T) posi‐
tion from the transcription starting place in a region closer to the promoter as well as a con‐
nection between the presence of the allele IL-8-251A and an increase in the production of
IL-8 and an elevated risk of gastric cancer development in the cardia. The presence of the
IL-8 251AA genotype was connected with increased risk of gastric cancer development in an
Asian population, mainly Han Chinese as well as in intestinal-type cancer [41,42].
2.14.3. Polymorphism of IL-10
Interleukine-10 (IL-10) is an anti-inflammatory cytokine which regulates the cell immuno‐
logical response. In the gene coding IL-10 three polymorphic promoter variants, located in
positions -1082 (A>G), -819 (T>C) and -592 (A>C) have been discovered. These variants are
connected with an elevated production of IL-10 and an increased risk of the occurrence of
gastric cancer, especially the intestinal non-cardia gastric cancer. What is more, polymor‐
phism of the gene coding IL-10 in combination with environmental factors, such as cigarette
smoking or an H. pylori infection creates favorable conditions for the occurrence and pro‐
gression of gastritis and carcinogenesis [43]. Additionally, polymorphism of IL-10 can influ‐
ence the immune system by changing the activity of the NK, T cells and macrophages and in
this manner influence the disease progression [44].
2.14.4. Polymorphism of IL-17A and IL-17F
Interleukin 17A and 17F are inflammatory cytokines, which play a critical role in inflamma‐
tion and probably in cancer. An association has been found between IL-17F A7488G poly‐
morphisms and the risk of intestinal-type gastric cancer. This polymorphism may influence
the multi-steps of gastric carcinogenesis. Furthermore, patients having IL-17F 7488GA geno‐
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type had increased risk of large tumor size and lymph- node metastasis. Positive associa‐
tions have been found between IL-17A 197AG genotype and elderly onset, early TNM stage
and poorly differentiated gastric cancers [45].
2.14.5. Polymorphism of TLR2 and TRL4
TRLs are important innate immunity receptors. TRL2 and TRL4 promote transcription of
genes involved in immune response activation including nuclear factor kappa B (NF-κB).
TRL2 activates NF-κB in response to H. pylori infection, causing the expression of IL-8. TRL4
up regulated in gastric epithelial cell infected by H. pylori; expression of the TRL4 protein
has been demonstrated in chronic active gastritis and in gastric tumor cells. It has been dem‐
onstrated that the presence of the TRL2-169 to -174del I TRL4+896G (Asp299Gly) polymor‐
phic variant can increase the risk of gastric cancer development, especially the non-cardia
intestinal-type [46-49].
2.14.6. Polymorphism of TP53
The TP53 gene is one of the most frequent targets for genetic mutations. The p53 pathway is
crucial for effective prevention of genetically damaged cell propagation, either directly, by
its participation in DNA repair mechanisms, or indirectly by induction of apoptosis. TP53
72ArgArg seems to be the survival factor for gastric cancer patients more advanced in years,
while the TP53 Pro-A1 plays the same role in younger patients with this type of tumor. Ad‐
ditionally tumors at more advanced stages (III and IV) showed TP53 intron 3 A2A2 geno‐
type carriers [50-52].
2.15. Gene mutations
2.15.1. CDH1 mutation
The germline CDH1 mutation is associated with the development of hereditary cancer syn‐
drome, called hereditary diffuse gastric cancer (HDGC). Germline mutation of the CDH1
gene has also been discovered in patients with sporadic early onset gastric cancer (EOGC).
Mutation of this gene has been described for the first time in 1998 in New Zealand in a
Maori family with history of diffused gastric cancer. Various types of CDH1 gene mutations
such as deletion, inertia, nonsense, and truncating have been described. The risk of develop‐
ing gastric cancer with the occurrence of a non-missense mutation of the CDH1 gene is high
at >80%, while with the occurrence of a missense mutation of this gene the risk has not been
defined [53-55].
CDH1 gene (E-cadherin gene), is one of the most important tumor suppressor genes in gas‐
tric cancer. The mutations, chromosomal deletions, epigenetic modifications have been re‐
ported as a mechanisms, that cause CDH1 inactivation. Somatic CDH1 mutations have been
found in about 50% of diffuse gastric cancer, germline mutations have been reported in fam‐
ilial gastric cancers.
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CANCER SITE CASES (%) BOTH SEXES ASR (world)
lip, oral cavity 263 2,1 3.9
Nosopharynx 84 0,7 1.2
other pharynx 135 1,1 0.2
Oesophagus 482 3,8 7.0
Stomach 989 7,8 14.1
Colorectum 1233 9,7 17.3
Liver 748 5,9 10.8
Gallbladder 145 1,1 2.0
Pancreas 277 2,2 3.9
Laryngx 151 1,2 2.3
Lung 1608 12,7 23.0
malanoma of skin 197 1,6 2.8
Kaposi sarcoma 34 0,3 0.5
Breast 1383 10,9 39.0
cervix uteri 529 4,2 15.2
corpus uteri 287 2,3 8.2
Ovary 225 1,8 6.3
Prostate 913 7,2 28.5
Testis 52 0,4 1.5
Kidney 271 2,1 3.9
Bladder 386 3 5.3
brain, nervous system 238 1,9 3.5
Thyroid 212 1,7 3.1
Hodkin lymphoma 67 0,5 1.0
non-Hodkin lymphoma 355 2,8 5.1
multiple myeloma 102 0,8 1.5
Leukemia 351 2,8 5.1
Table 1. Estimated new cancer cases (thousands), ASRs (per 100,000) and cumulative risks (percent) by sex and cancer
site worldwide, 2008 [64].
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CANCER SITE DEATHS (%) BOTH SEXES ASR (world)
lip, oral cavity 127 1.7 1.9
Nosopharynx 51 0.7 0.8
other pharynx 95 1.3 1.4
Oesophagus 406 5.4 5.8
Stomach 738 9.7 10.3
Colorectum 608 8.0 8.2
Liver 695 9.2 10.0
Gallbladder 109 1.4 1.5
Pancreas 266 3.5 3.7
Laryngx 82 1.1 1.2
Lung 1378 18.2 19.4
malanoma of skin 46 0.6 0.6
Kaposi sarcoma 29 0.4 0.4
Breast 458 6.0 12.5
cervix uteri 274 3.6 7.8
corpus uteri 74 1.0 2.0
Ovary 140 1.8 3.8
Prostate 258 3.4 7.5
Testis 9 0.1 0.3
Kidney 116 1.5 1.6
Bladder 150 2.0 2.0
brain, nervous system 174 2.3 2.6
Thyroid 35 0.5 0.5
Hodkin lymphoma 30 0.4 0.4
non-Hodkin lymphoma 191 2.5 2.7
multiple myeloma 72 1.0 1.0
Leukemia 257 3.4 3.6
Table 2. Estimated cancer deaths (thousands), ASRs (per 100,000) and cumulative risks (percent) by sex and cancer
site worldwide, 2008 [64].
Gastric Carcinoma- New Insights into Current Management64
REGION MALE FEMALE
Eastern Africa 4.0 3.3
Middle Africa 1.7 1.8
Northern Africa 2.9 1.9
Southern Africa 0.7 0.5
Western Africa 3.3 2.6
Caribbean 2.4 1.6
Central America 7.7 6.5
South America 29.3 17.9
Northen America 15.1 9.4
Eastern America 408.2 193.1
South-Eastern Asia 24.9 18.4
South-Central Asia 41.9 26.2
Western Asia 9.2 5.6
Cenral and Eastern Europe 43.3 30.6
Northern Europe 7.8 4.9
Southern Eutope 20.0 12.9
Western Europe 16.5 10.9
Australia/New Zealand 1.5 0.8
Melanesia 0.2 0.1
Micronesia/Polynesia 0.0 0.0
Table 3. Estimated numbers of new gastric cancer cases (thousands) by sex and regions, 2008 [64].
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REGION MALE FEMALE
Eastern Africa 3.8 3.1
Middle Africa 1.6 1.7
Northern Africa 2.7 1.8
Southern Africa 0.6 0.5
Western Africa 3.1 2.5
Caribbean 1.8 1.2
Central America 6.4 5.6
South America 24.2 15.1
Northen America 7.6 5.2
Eastern America 274.3 144.2
South-Eastern Asia 20.1 15.3
South-Central Asia 39.5 24.1
Western Asia 8.1 4.9
Cenral and Eastern Europe 38.2 26.6
Northern Europe 5.4 3.6
Southern Eutope 14.6 9.8
Western Europe 11.1 7.9
Australia/New Zealand 0.9 0.6
Melanesia 0.2 0.1
Micronesia/Polynesia 0.0 0.0
Table 4. Estimated numbers of gastric cancer deaths (thousands) by sex and regions, 2008 [64].
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2.15.2. DNA methylation
DNA methylation is an epigenetic mechanism regulating transcription which in cancer is at‐
tributed to the inappropriate silencing of tumor suppressor genes, or loss of oncogene re‐
pression. Methylation pattern of DNA can be useful in assessing the risk of cancer
occurrence, prognosis and success of treatment. Aberrant DNA methylation appears in early
stages of carcinogenesis, which makes it especially useful to predict the risk of contracting
cancer. Methylated DNA is stable and has a high detectability (as much as 1:1000 particles)
in biological fluids. What is more, in cancer patients DNA methylation can be an indicator of
an answer for applied chemotherapy as well as can indicate a shorter time of post-operative
survival [56-59].
2.15.3. RUNX3 promoter methylation
Runt-related transcription factor (RUNX3), a member of the runt domain family of tran‐
scription factors, plays an important role in the signaling path of the TGF-β (transforming
growth factor β). In many reports not only the role of the RUNX3 in the correct development
but also in the progression of cancer has been demonstrated. It has been shown that in
younger gastric cancer patients the methylation of the RUNX3 promoter was associated
with histological type and level of tumor differentiation. It has been suggested that RUNX3
promoter methylation or down-regulation of the RUNX3 gene may be related to a poor
prognosis [60,61].
2.15.4. CHRF promoter methylation
CHRF (checkpoint with FHA and RING finger) is an important tumor suppressor gene.
CHRF encodes a protein within the FHA and RING finger domain that governs transition
from prophase to metaphase in the mitotic checkpoint pathway. Aberrant methylation of the
CHRF gene is a frequent event in gastric cancer. The methylation rate of CHRF gene in
stomach carcinoma was significantly higher than in paired normal gastric mucosa and it
was associated with poorly differentiated tumor cells. Also, CHRF gene methylation was as‐
sociated with the degree of malignancy of gastric cancer. The CHRF mRNA or protein ex‐
pression level was down-regulated or loss [62,63].
3. Conclusion
Gastric carcinogenesis is a complex multistep process resulting from the interaction between
genome and environmental factors. Many exogenous factors seem to contribute to the initia‐
tion of carcinogenesis in the stomach, including diet (especially high in salt, smoked or pick‐
led foods, grilled meats or smoked fish), chronic a trophic gastritis with intestinal
metaplasia, gastric ulcer, dysplasia, and partial resection of gastric polyps. Others risk fac‐
tors for this cancer is chemical agents and infections, e. g. caused by Helicobacter pylori and
Epstein- Barr virus. Also, genetic factors, such as blood group A, familial polyposis and the
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presence of gastric cancer among family members play a role in the development of this can‐
cer. This group of factors also include radiation or pernicious anemia. Additionally, dys‐
function of CDH1 gene (E-cadherin-coding gene) together with mutation have been found
in diffuse-type gastric carcinoma. Mutation in CDH1 is a genetic defect found in approxi‐
mately 1/3 of familial gastric cancers such as hereditary diffuse gastric cancers (HDGC). Al‐
so, the presence of single nucleotide polymorphisms (SNPs) in several genes can modulate
the risk of gastric cancer.
Knowledge of various risk factors for stomach cancer can help to determined the risk of de‐
velopment this cancer. Also, a small change in diet or lifestyle can significantly reduce this
risk.
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